Literature DB >> 22088239

[2010 Chinese guidelines for the management of hypertension].

Li-Sheng Liu1.   

Abstract

The 2010 Chinese guidelines for the management of hypertension is an update of the previous versions in 2005 and 1999. A guideline committee of nearly 100 members appointed by the Chinese Hypertension League (CHL) and the National Centre for Cardiovascular Disease (NCCD), in collaboration with the Chinese societies of cardiology, nephrology, neurology, gynecology and endocrinology, convened on several occasions and discussed the guidelines, drafted by a core writing group. The prevalence of hypertension has been increasing in China for decades, and reached 18.8% in the year 2002. The rates of awareness, treatment and control for hypertension patients remain low compared to high income countries, in spite of substantial improvements since 1991. In some communities, the control rate of hypertension increased up to 60%. The mortality rate of stroke, which is the major complication of hypertension in the Chinese population, gradually decreased during the period, more so in urban areas than in rural areas for the middle-aged and elderly populations; in the younger age groups, however, it increased. As hypertension is a "cardiovascular syndrome", the management strategy should be based on the overall risk of cardiovascular disease estimated with all related risk factors, target organ damage and co-morbidity of patients. The target blood pressure is set at SBP/DBP < 140/90 mm Hg (1 mm Hg = 0. 133 kPa) in uncomplicated hypertension; < 150/90 mm Hg for the elderly (> or = 65 years) or, if tolerable, < 140/90 mm Hg; and < 130/80 mm Hg for those with diabetes, coronary heart disease or renal disease. For these high risk patients, the management should be individualised. In general, lifestyle modification, such as sodium restriction, smoking cessation, moderation of body weight and alcohol consumption, and increasing dietary potassium intake and physical activity, should be implemented for prevention and control of hypertension. Five classes of antihypertensive drugs, including calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin type II receptor blockers, diuretics and beta-blockers, as well as single pill combinations of these agents, can be used for initial and maintenance of antihypertensive treatment. Several populations require special attention in the prevention and control of hypertension, such as children and adolescents, the elderly, pregnant women, and patients with various cardiovascular complications. Since health-care policies and resources vary substantially from one place to another, two levels of recommendations of management are proposed: a sophisticated and a basic, allowing doctors-in-charge to manage their patients in a more feasible way.

Entities:  

Mesh:

Year:  2011        PMID: 22088239

Source DB:  PubMed          Journal:  Zhonghua Xin Xue Guan Bing Za Zhi        ISSN: 0253-3758


  327 in total

1.  Correlations between brachial endothelial function and cardiovascular risk factors: a survey of 2,511 Chinese subjects.

Authors:  Ping-Ting Yang; Hong Yuan; Ya-Qin Wang; Xia Cao; Liu-Xin Wu; Zhi-Heng Chen
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 2.  Barriers to translating EU and US CVD guidelines into practice in China.

Authors:  Dong Zhao; Dayi Hu
Journal:  Nat Rev Cardiol       Date:  2012-05-01       Impact factor: 32.419

3.  Hypertension Guidelines: Timely New Initiatives from East Asia.

Authors:  John Chalmers
Journal:  Pulse (Basel)       Date:  2015-04-29

4.  The prevalence and adverse profiles of fatty liver disease among different ethnic public servants in Urumqi of Xinjiang Uygur Autonomous Region in China.

Authors:  Dan Chen; Jie Guan; Xiang Xie; Wei-Yun Zhao; Palida Abulaiti; Yu Wang; Zhi-Qin Cheng; Jing Zhang; Ying Gao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

5.  Hyperuricemia and severity of coronary artery disease: An observational study in adults 35 years of age and younger with acute coronary syndrome.

Authors:  Sai Lv; Wei Liu; Yujie Zhou; Yuyang Liu; Dongmei Shi; Yingxin Zhao; Xiaoli Liu; Jumana W Alhelal; K S Shakeenah Ravuru
Journal:  Cardiol J       Date:  2018-03-07       Impact factor: 2.737

Review 6.  Unique approaches to hypertension control in China.

Authors:  Ji-Guang Wang
Journal:  Ann Transl Med       Date:  2018-08

7.  Analysis of the risk factors and characteristics of coronary artery disease of Han, Uygur and Kazak patients with acute myocardial infarction in Xinjiang district.

Authors:  Jiao Wang; Zhi-Qiang Liu; Peng-Yi He; Yu-Chun Yang; Lei Zhang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

8.  Applying a "Big Data" Literature System to Recommend Antihypertensive Drugs for Hypertension Patients with Diabetes Mellitus.

Authors:  Jing-Xian Shu; Ying Li; Ting He; Ling Chen; Xue Li; Lin-Lin Zou; Lu Yin; Xiao-Hui Li; An-Li Wang; Xing Liu; Hong Yuan
Journal:  Med Sci Monit       Date:  2018-01-07

9.  Is the grading system of the severity of the OSAHS used presently rational or not?: from the view of incidence of hypertension in different severity groups.

Authors:  Jinrang Li; Xi Chen; Jianjun Sun
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-23       Impact factor: 2.503

Review 10.  Gaps in Hypertension Guidelines in Low- and Middle-Income Versus High-Income Countries: A Systematic Review.

Authors:  Mayowa Owolabi; Paul Olowoyo; J Jaime Miranda; Rufus Akinyemi; Wuwei Feng; Joseph Yaria; Tomiwa Makanjuola; Sanni Yaya; Janusz Kaczorowski; Lehana Thabane; Josefien Van Olmen; Prashant Mathur; Clara Chow; Andre Kengne; Raelle Saulson; Amanda G Thrift; Rohina Joshi; Gerald S Bloomfield; Mulugeta Gebregziabher; Gary Parker; Charles Agyemang; Pietro Amedeo Modesti; Shane Norris; Luqman Ogunjimi; Temitope Farombi; Ezinne Sylvia Melikam; Ezinne Uvere; Babatunde Salako; Bruce Ovbiagele
Journal:  Hypertension       Date:  2016-10-03       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.